Genetic factors and hepatitis C virus infection

Gastroenterology

Volumn 142, Issue 6, 2012, Pages 1335-1339

  Thompson, Alexander J ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

DAA; direct acting antiviral agent; HCV; hepatitis C virus; inosine triphosphatase; interferon stimulated genes; ISG; ITPase; pegIFN; peginterferon alfa; RBV; ribavirin; single nucleotide polymorphisms; SNP; sustained virological response; SVR

Indexed keywords

BOCEPREVIR; INOSINE TRIPHOSPHATASE; INTERLEUKIN 28B; PEGINTERFERON ALPHA; PHOSPHATASE; RIBAVIRIN; TELAPREVIR; UNCLASSIFIED DRUG;

CHROMOSOME 19; GENE EXPRESSION; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HEREDITY; HUMAN; NONHUMAN; NOTE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

EID: 84860290308     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2012.01.046     Document Type: Article

References (41)

1. D. Ge, J. Fellay, A.J. Thompson Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
2. Y. Tanaka, N. Nishida, M. Sugiyama Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nat Genet 41 2009 1105 1109
3. V. Suppiah, M. Moldovan, G. Ahlenstiel IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nat Genet 41 2009 1100 1104
4. A. Rauch, Z. Kutalik, P. Descombes Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study Gastroenterology 138 2010 1338 1345 1345 e1-e7
5. T.A. Manolio, F.S. Collins, N.J. Cox Finding the missing heritability of complex diseases Nature 461 2009 747 753
6. T.A. Pearson, T.A. Manolio How to interpret a genome-wide association study JAMA 299 2008 1335 1344
7. J. Hardy, A. Singleton Genomewide association studies and human disease N Engl J Med 360 2009 1759 1768
8. D.L. Thomas, C.L. Thio, M.P. Martin Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Nature 461 2009 798 801
9. J. Grebely, K. Petoumenos, M. Hellard Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection Hepatology 52 2010 1216 1224
10. H.L. Tillmann, A.J. Thompson, K. Patel A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice Gastroenterology 139 2010 1586 1592 1592 e1
11. P.Y. Bochud, S. Bibert, F. Negro IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C J Hepatol 55 2011 980 988
12. A.J. Thompson, A.J. Muir, M.S. Sulkowski Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus Gastroenterology 139 2010 120 129 e18
13. N.I. Rallon, S. Naggie, J.M. Benito Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients AIDS 24 2010 F23 F29
14. M.R. Charlton, A. Thompson, B.J. Veldt Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection Hepatology 53 2011 317 324
15. T. Fukuhara, A. Taketomi, T. Motomura Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C Gastroenterology 139 2010 1577 1585 1585 e1-e3
16. T.M. Scherzer, A.F. Stattermayer, M. Strasser Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin Hepatology 54 2011 1518 1526
17. T. Asselah, S. De Muynck, P. Broet IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C J Hepatol 56 2012 527 532
18. S. De Nicola, A. Aghemo, M.G. Rumi An IL28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4 Hepatology 55 2012 336 342
19. A. Mangia, A.J. Thompson, R. Santoro An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response Gastroenterology 139 2010 821 827 827 e1
20. W.K. Seto, Y. Tanaka, K. Liu The effects of IL-28B and ITPA polymorphisms on treatment of hepatitis C virus genotype 6 Am J Gastroenterol 106 2011 1007 1008
21. B. Efron, R. Tibshirani An introduction to the bootstrap 1997 Chapman and Hall London
22. M. Honda, A. Sakai, T. Yamashita Hepatic ISG expression is associated with genetic variation in IL28B and the outcome of IFN therapy for chronic hepatitis C Gastroenterology 139 2010 499 509
23. T.J. Urban, A.J. Thompson, S.S. Bradrick IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C Hepatology 52 2010 1888 1896
24. A.J. Muir, E. Lawitz, R.H. Ghalib Pegylated interferon lambda (PEG-IFN-λ) phase 2 dose-ranging, active controlled study in combination with ribavirin (RBV) for treatment naive HCV patients (genotype 1,2,3 or 4): safety, viral response and impact of IL28B host genotype through week 12 Hepatology 52 2010 821 (abstract)
25. M.T. Dill, F.H. Duong, J.E. Vogt Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C Gastroenterology 140 2011 1021 1031 e10
26. F. Poordad, J. McCone Jr, B.R. Bacon Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
27. I.M. Jacobson, J.G. McHutchison, G. Dusheiko Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
28. I.M. Jacobson, I. Catlett, P. Marcellin Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial J Hepatol 54 2011 Abstract 1369
29. S. Pol, J. Aerssens, S. Zeuzem Similar SVR rates in IL28B CC, CT or TT prior relapser, partial- or null-responder patients treated with telaprevir/peginterferon/ribavirin: retrospective analysis of the REALIZE study J Hepatol 54 2011 S6 (A13)
30. F. Poordad, J.P. Bronowicki, S. Gordon IL28B polymorphism predicts virologic response in patients with hepatitis C genotype 1 treated with boceprevir (BOC) combination therapy J Hepatol 54 2011 S6
31. M. Fried, M. Buti, G.J. Dore TMC435 in combination with peginterferon and ribavirin in treatment-naive HCV genotype 1 patients: final analysis of the PILLAR phase IIB study Hepatology 54 2011 1429A (LB-5)
32. E. Lawitz, J.P. Lalezari, T. Hassanein Once-daily PSI-7977 plus PEG/RBV in treatment-naive patients with HCV Gt1: robust end-of-treatment response rates are sustained post-treatment Hepatology 54 2011 472A (225)
33. K. Chayama, S. Takahashi, Y. Kawakami Dual oral combination therapy with the NS5A inhibitor BMS-790052 and the NS3 protease BMS-650032 achieved 90% sustained virologic response (SVR12) in HCV genotype 1B-infected null responders Hepatology 54 2011 1428A (LB-4)
34. J. Fellay, A.J. Thompson, D. Ge ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C Nature 464 2010 405 408
35. Y. Hitomi, E.T. Cirulli, J. Fellay Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function Gastroenterology 140 2011 1314 1321
36. A.J. Thompson, J. Fellay, K. Patel Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction Gastroenterology 139 2010 1181 1189
37. A. Mas Marques, T. Mueller, J. Welke Low-density lipoprotein receptor variants are associated with spontaneous and treatment-induced recovery from hepatitis C virus infection Infect Genet Evol 9 2009 847 852
38. M.S. Sulkowski, K.R. Reddy, L.D. Pedicone ITPA deficiency is associated with lower rates of anemia and EPO use in patients treated with boceprevir (BOC) plus peginterferon/ribavirin (PR) Hepatology 54 2011 798A (934)
39. A.J. Thompson, P.J. Clark, H.L. Tillmann IL28B C/C genotype is predictive of >=1 log10 IU/mL reduction in plasma HCV RNA after 48 weeks of peginterferon (PEGIFN) and ribavirin (RBV) therapy: implications for the use of the lead-in strategy for direct acting antiviral-based treatment regimens Hepatology 54 2011 437A (158)
40. Z.F. Gellad, S. Naggie, S.D. Reed The cost-effectiveness of a telaprevir-inclusive regimen as initial therapy for genotype 1 hepatitis C infection in individuals with the C/C IL28B polymorphism Hepatology 54 Suppl 2011 417A (118)
41. A.J. Thompson, A.J. Muir, M.S. Sulkowski Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype Hepatology 52 2010 2243 2244